Answers are grounded in this paper and cite their sources.
Molecular assays demonstrate WT1 represses IGF-II transcription via promoter binding, indicating a mechanism for growth factor overexpression in Wilms tumors.
The Wilms tumor suppressor gene wt1 encodes a zinc finger DNA binding protein, WT1, that functions as a transcriptional repressor. The fetal mitogen insulin-like growth factor II (IGF-II) is overexpressed in Wilms tumors and may have autocrine effects in tumor progression. The major fetal IGF-II promoter was defined in transient transfection assays as a region spanning from nucleotides -295 to +135, relative to the transcription start site. WT1 bound to multiple sites in this region and functioned as a potent repressor of IGF-II transcription in vivo. Maximal repression was dependent on the presence of WT1 binding sites on each side of the transcriptional initiation site. These findings provide a molecular basis for overexpression of IGF-II in Wilms tumors and suggest that WT1 negatively regulates blastemal cell proliferation by limiting the production of a fetal growth factor in the developing vertebrate kidney.
No takes yet. Share an insight, caveat, or question.
Drummond et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: